NCT06581393 is a NA clinical trial of Moda-flx Hemodialysis System in End Stage Renal Disease, sponsored by Diality Inc..

Who is sponsoring NCT06581393?

NCT06581393 is sponsored by Diality Inc..

What drugs are being tested in NCT06581393?

Interventions in NCT06581393: Moda-flx Hemodialysis System.

What condition does NCT06581393 study?

NCT06581393 studies End Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Kidney Disease.

Is NCT06581393 still recruiting?

NCT06581393 is currently completed. Last updated 22 June 2025.

Last reviewed 2025-06-22 · How we verify

NCT06581393

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First Evaluation of the Moda-Flx Hemodialysis System™ in Real World Clinical Settings

Completed NA Last updated 22 June 2025

What this trial tests

NA trial testing Moda-flx Hemodialysis System in End Stage Renal Disease in 12 participants. Completed in 28 April 2025.

Timeline

9 December 2024

Primary endpoint
28 April 2025

28 April 2025

Quick facts

Lead sponsor	Diality Inc.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	9 December 2024
Primary completion	28 April 2025
Estimated completion	28 April 2025
Sites	1 location across United States

Drugs / interventions tested

Moda-flx Hemodialysis System

Conditions studied

End Stage Renal Disease — all drugs for End Stage Renal Disease →
End Stage Renal Disease on Dialysis — all drugs for End Stage Renal Disease on Dialysis →
End Stage Kidney Disease — all drugs for End Stage Kidney Disease →

Sponsor

Diality Inc.

Who can join

18 and older, any sex, with End Stage Renal Disease or End Stage Renal Disease on Dialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a non-significant risk study utilizing a device cleared for use by the FDA under its 510(k) clearance. Consented patients will complete their usual dialysis treatment under professional care in an ICHD (In-Center Hemodialysis) setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for End Stage Renal Disease

Currently open trials in the same condition.

NCT06257134 — Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients. · NA · recruiting
NCT06310161 — Light Therapy in End Stage Kidney Disease · NA · recruiting
NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
NCT06422871 — PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis · recruiting
NCT06861816 — Ventilatory Functions and Physical Intolerance in ESRD Adolescents: Response to Program of Walking With Dogs · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06581393 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Diality Inc.
Last refreshed: 22 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06581393.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing